GlobeNewsWire
25 Oct 2025, 13:59 UTC · 45w ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
4 claims · each scored for market impact
Additional analyses from the pivotal Phase 3 pHalcon-NERD-301 trial evaluating VOQUEZNA in Non-Erosive Reflux Disease (NERD) have been published in the American Journal of Gastroenterology. — Peer-reviewed publication of pivotal Phase 3 data validates the efficacy claims for a new indication, enhancing physician adoption and commercial credibility for the drug.
+0.60The published data specifically demonstrates that VOQUEZNA improves nocturnal gastroesophageal reflux symptoms in NERD, an undertreated condition affecting up to 80% of GERD patients. — Demonstrating efficacy in a prevalent, inadequately managed symptom like nighttime GERD differentiates VOQUEZNA from existing standard therapies and expands its addressable market.
+0.55An estimated 38 million U.S. adults have Non-Erosive GERD, with approximately 15 million treated with a prescription medicine annually. — Quantifying the large prescription-treated population establishes the significant commercial revenue opportunity for a newly approved therapy in this indication.
+0.45Continue reading
5 related stories
Search tags
The study highlights that many patients experience inadequate relief of nocturnal symptoms despite widespread use of PPIs and H2RAs. — Emphasizing the failure of current standard-of-care therapies strengthens the competitive positioning and market uptake potential for VOQUEZNA as a superior alternative.
+0.30Which stocks this story touches
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
WSJ
6d ago
